Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Loading news article.

Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated | WAPE

Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated

Article summary

Related companies

Analyzed by WAPE AI.

Comments —